CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
dmmr
A collection of 120 issues
CRC Research Update — August 19, 2026
Today's colorectal cancer research highlights
Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC
Skip to content
The CRC Digest
Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC
A multicenter real-world study from four Chinese hospitals evaluated long-term outcomes of a watch-and-wait strategy in stage II/III dMMR/MSI-H colorectal cancer patients who achieved endoscopic complete response after neoadjuvant anti-PD-1 monotherapy. (Frontiers in Immunology)
CRC Research Update — August 18, 2026
Today's colorectal cancer research highlights
DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC
Skip to content
The CRC Digest
◇ RESEARCH
DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC
A new study identifies the dihydropyrimidine dehydrogenase (DPD) metabolic pathway as the first predictor of immune checkpoint inhibitor efficacy in MSI-H tumors, potentially helping identify patients at risk for resistance. (Journal for ImmunoTherapy
CRC Research Update — August 13, 2026
Today's colorectal cancer research highlights
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer
An indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4
Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC
Skip to content
The CRC Digest
Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC
A Chinese study used a three-state partitioned survival model to evaluate nivolumab plus ipilimumab versus nivolumab monotherapy in previously treated metastatic colorectal cancer patients with dMMR/MSI-H, using Kaplan-Meier curves
CRC Research Update — August 09, 2026
Today's colorectal cancer research highlights
Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC
A study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)